Avanir, Opexa gain ahead of presentations

The drug sector's two leading indices slip into negative territory in early activity while shares of Avanir Pharmaceuticals break from the pack, gaining on news that analysts at Canaccord Adams have initiated coverage of the stock with a buy rating.